Dianthus Therapeutics Inc (NAS:DNTH)
$ 21.54 0.91 (4.4%) Market Cap: 632.19 Mil Enterprise Value: 231.00 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 22/100

Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 09:40PM GMT
Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

Okay. Great. I think we're going to get started here. I'm Terence Flynn, one of the biotech analysts at Goldman. And we're very pleased to have Magenta Therapeutics with us this afternoon. Joining us from the company is Jason Gardner, President and CEO.

Jason, thanks so much for being here with us this afternoon. Maybe just to start, given how new of a company you guys are, would just love a brief overview to kind of the formation of the company, the strategy and then why transplant. Like, why did you guys elect to focus there because it is somewhat novel in terms of the approach, and also taking this portfolio approach is somewhat different as well.

Jason Gardner
Magenta Therapeutics, Inc. - Co-Founder, CEO, President & Director

Well, first of all, Terence, thank you. Thank you for having me here and representing Magenta. It's a great pleasure. So we'll start at the end of that question, so why did we build Magenta, why transplant, why itâs this unique? So what we know is that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot